nanotopographies optimized to facilitate biomolecular delivery, genome editing, and cellular modulation-have enormous potential to build capacity over a range of collaborating disciplines associated with biomedical research. High-aspect-ratio nanostructures are now providing major advantages in precise manipulation of increasingly complex cellular processes, assisting the translation into clinical applications such as tissue engineering, regenerative medicine, drug delivery, biosensing, and cancer immunotherapies. [2-5] In particular, 1D vertical nanostructures (1D-VNS)-nanowires, nanoneedles, nanopillars, nanotubes, nanosyringes, nanostraws, nanocones, and nanospikes (Figure 1a)-have helped tackle various biological problems such as intracellular recording and genetic interrogation. [6-16] Unlike other highaspect-ratio nanostructures, such as freestanding carbon nanotubes, 1D-VNS can be rationally designed and synthesized, via top-down and/or bottom-up approaches, with defined key parameters-including topological geometry (pitch, diameter, length), chemical composition, doping, and electronic propert ies. [17-21] So by well-controlled programming coupled with selective surface functionality, 1D-VNS can provide unprecedented spatial and mechanical resolution to enable direct, Engineered nano-bio cellular interfaces driven by 1D vertical nanostructures (1D-VNS) are set to prompt radical progress in modulating cellular processes at the nanoscale. Here, tuneable cell-VNS interfacial interactions are probed and assessed, highlighting the use of 1D-VNS in immunomodulation, and intracellular delivery into immune cells-both crucial in fundamental and translational biomedical research. With programmable topography and adaptable surface functionalization, 1D-VNS provide unique biophysical and biochemical cues to orchestrate innate and adaptive immunity, both ex vivo and in vivo. The intimate nanoscale cell-VNS interface leads to membrane penetration and cellular deformation, facilitating efficient intracellular delivery of diverse bioactive cargoes into hard-to-transfect immune cells. The unsettled interfacial mechanisms reported to be involved in VNS-mediated intracellular delivery are discussed. By identifying up-to-date progress and fundamental challenges of current 1D-VNS technology in immune-cell manipulation, it is hoped that this report gives timely insights for further advances in developing 1D-VNS as a safe, universal, and highly scalable platform for cell engineering and enrichment in advanced cancer immunotherapy such as chimeric antigen receptor-T therapy.